7399-67-9

Basic information

• Product Name: 2-(2-BROMOACETYL)BENZOIC ACID
• Synonyms: 2-BROMO-1-(2-CARBOXYPHENYL)ETHANONE;2-(2-BROMOACETYL)BENZOIC ACID
• CAS NO: 7399-67-9
• Molecular Formula: C₉H₇BrO₃
• Molecular Weight: 243.05
• Mol File: 7399-67-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 116-117°C
• Boiling Point: 366.5 °C at 760 mmHg
• Flash Point: 175.4 °C
• Appearance: /
• Density: 1.657 g/cm³
• Vapor Pressure: 5.14E-06mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-BROMOACETYL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-BROMOACETYL)BENZOIC ACID(7399-67-9)
• EPA Substance Registry System: 2-(2-BROMOACETYL)BENZOIC ACID(7399-67-9)

Safety Data

• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• Hazardous Substances Data: 7399-67-9(Hazardous Substances Data)

Usage

General Description

2-(2-Bromoacetyl)benzoic acid, also known as Bromoacetylbenzoic acid, is a chemical compound with the molecular formula C9H7BrO3. It is a white to off-white crystalline powder with a molecular weight of 241.06 g/mol. 2-(2-BROMOACETYL)BENZOIC ACID is commonly used in organic synthesis as a reagent for the preparation of various pharmaceuticals and agrochemicals. It is also used in the manufacturing of dyes and pigments. When handled, it should be stored in a cool, dry place and kept away from sources of ignition and incompatible materials. 2-(2-Bromoacetyl)benzoic acid is considered to be a hazardous substance and should be handled and disposed of according to proper safety protocols.

InChI:InChI=1/C9H7BrO3/c10-5-8(11)6-3-1-2-4-7(6)9(12)13/h1-4H,5H2,(H,12,13)

Upstream product

• 577-56-0 2-acetyl-benzoic acid 
• 85-44-9 phthalic anhydride 
• 477338-22-0 2-(1-Butoxy-vinyl)-benzoic acid methyl ester 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 1077-79-8 methyl 2-acetylbenzoate 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 

Downstream Products

• 1421922-93-1 2-{2-[4-({(E)-[ethyl(methyl)amino]methylidene}amino)-2,5-dimethylbenzyl]-1,3-thiazol-4-yl}benzoic acid hydrobromide 
• 65254-44-6 5-acetyl-3-phenyl-5H-thiazolo[4,3-a]isoindolylium; bromide 
• 65032-69-1 3-phenyl-5H-thiazolo<4,3-a>isoindolium bromide 
• 65032-71-5 1-methyl-2a-phenyl-2-oxa-3-thia-8c-aza-pentaleno[1,6-ab]indene 
• 65032-67-9 [2-(2-phenyl-thiazol-4-yl)-phenyl]-methanol 
• 65032-68-0 [2-(2-methyl-thiazol-4-yl)-phenyl]-methanol 
• 854395-16-7 5-oxo-6-phenyl-5,6-dihydro-dibenzo[b,h][1,5]naphthyridine-7-carboxylic acid 
• 96276-73-2 3-[2-(3-ethyl-4,5-diphenyl-3H-oxazol-2-ylidene)-ethylidene]-isochroman-1,4-dione 
• 160322-93-0 2-[2-(3,4-Diethoxy-phenyl)-thiazol-4-yl]-benzoic acid methyl ester 
• 5693-27-6 isochroman-1,4-dione 
• 748121-40-6 2-(2-amino-thiazol-4-yl)-benzoic acid 
• 65032-66-8 2-(2-methyl-thiazol-4-yl)-benzoic acid 

Relevant articles and documents

Nucleus-independent chemical shift (NICS) as a criterion for the design of new antifungal benzofuranones

The assertion made by Wu et al. that aromaticity may have considerable implications for molecular design motivated us to use nucleus-independent chemical shifts (NICS) as an aromaticity criterion to evaluate the antifungal activity of two series of indol-4-ones. A linear regression analysis of NICS and antifungal activity showed that both tested variables were significantly related (p –1 for Candida glabrata, Candida krusei and Candida guilliermondii with compounds 15-32, 15-15 and 15-1. The MIC for filamentous fungi was 1.95 μg·mL–1 for Aspergillus niger for compounds 15-1, 15-33 and 15-34. The results obtained support the use of NICS in the molecular design of compounds with antifungal activity.

Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites

ARQ 501 (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b] pyran-5,6-dione), a synthetic version of β-Lapachone, is a promising anti-cancer agent currently in multiple Phase II clinical trials. Promising anti-cancer activity was observed in Phase I and Phase II trials. Metabolism by red blood cells of drugs is an understudied area of research and the metabolites arising from oxidative ring opening (M2 and M3), decarbonylation/ring contraction (M5), and decarbonylation/oxidation (M4 and M6) of ARQ 501 offer a unique opportunity to provide insight into these metabolic processes. Since these metabolites were not detected in in vitro incubations of ARQ 501 with liver microsomes and were structurally diverse, confirmation by chemical synthesis was considered essential. In this report, we disclose the synthetic routes employed and the characterization of the reference standards for these blood metabolites as well as additional postulated structures, which were not confirmed as metabolites.

Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: Synthesis and structure-activity relationships

Neutrophils have an important role in the self-defense systems of organisms through the production of superoxide. On the other hand, it has been proposed that abnormal amounts of superoxide produced by neutrophils are a serious factor in tissue injury. A series of novel thiazole derivatives was prepared and evaluated inhibitory effect on superoxide production by human neutrophils in vitro. Among these compounds, 6-[2-(3,4- diethoxyphenyl)thiazol-4-yl]-pyridine-2-carboxylic acid (OPC-6535) was selected as one of the most promising compounds. The synthesis and structure- activity relationships of these compounds are reported herein.